Prophylactic Human Vaccine Market Size, Share, Outlook, and Opportunity Analysis, 2022-2028

 

Prophylactic Human Vaccine Market
Prophylactic Human Vaccine Market

Prophylactic human vaccinations boost the immune response and are intended to decrease the impact of potential pathogen-caused diseases in humans. Novel vaccine production technologies are being used to generate Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) vaccines. The Human Papillomavirus is a family of over 200 viruses, more than 40 of which are transmitted by direct sexual contact. Several HPV viruses have been linked to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers.

During the projected period, the prophylactic human vaccine market    is expected to grow due to an increase in pipeline research and increased involvement of key players in vaccine development. CureVac AG, for example, announced in October 2018 that it would begin a dose escalation phase I clinical trial for CV7202 mRNA-based rabies vaccine. CV7202 is a preventive vaccine that contains the rabies virus glycoprotein RABV-G. This allows vaccinated individuals' own cells to manufacture RABV-G protein, triggering an immunological response. The investigation is expected to be completed in January 2021.

Furthermore, in October 2018, Valneva SE reported success in its Phase 1 programme aimed at developing a single-dose vaccine against Chikungunya. It is intended for single-dose preventive immunisation against Chikungunya in humans. The vaccine is designed to provide long-lasting protection with a safety profile similar to other authorised vaccines for active vaccination in adults and children.

Comments

Popular posts from this blog

The Role of the Foodservice Industry in Driving the French Fries Market

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities